We report here a patient with TSC and ADPKD due to independent mutations in both TSC2 and PKD1 who was treated with mTOR inhibitors showing a good response based on AML and cystic burden decrease but without preservation of renal function. This evidence concerns the gene PKD1 and autosomal dominant polycystic kidney disease.